Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation.

Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, Carrier M, Coyle K, Bai A, Moulton K, Clifford T, Wells G.

BMJ Open. 2014 Jun 2;4(6):e004301. doi: 10.1136/bmjopen-2013-004301. Review.

2.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

3.

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.

Salazar CA, del Aguila D, Cordova EG.

Cochrane Database Syst Rev. 2014 Mar 27;(3):CD009893. doi: 10.1002/14651858.CD009893.pub2. Review.

PMID:
24677203
4.

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Skjøth F, Larsen TB, Rasmussen LH, Lip GY.

Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118.

PMID:
24577485
5.

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.

Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M.

Circulation. 2015 Jul 21;132(3):194-204. doi: 10.1161/CIRCULATIONAHA.114.013267. Review.

6.

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.

Bruins Slot KM, Berge E.

Cochrane Database Syst Rev. 2013 Aug 8;(8):CD008980. doi: 10.1002/14651858.CD008980.pub2. Review.

PMID:
23925867
8.

Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.

Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.

Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084.

PMID:
26655548
9.
10.

Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients.

Dogliotti A, Paolasso E, Giugliano RP.

Heart. 2014 Mar;100(5):396-405. doi: 10.1136/heartjnl-2013-304347. Review.

PMID:
24009224
11.

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation.

Dzeshka MS, Lip GY.

Heart Fail Clin. 2016 Apr;12(2):257-71. doi: 10.1016/j.hfc.2015.08.021. Review.

PMID:
26968670
12.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988.

13.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Review.

PMID:
24383983
14.
15.

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.

Lane DA, Raichand S, Moore D, Connock M, Fry-Smith A, Fitzmaurice DA; Steering Committee..

Health Technol Assess. 2013 Jul;17(30):1-188. doi: 10.3310/hta17300. Review.

16.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019.

17.

Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.

Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Gonçalves N, Pinto FJ, Ferreira JJ, Costa J.

Heart. 2015 Aug;101(15):1204-11. doi: 10.1136/heartjnl-2015-307489. Review.

PMID:
26037103
18.

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P.

Clin Pharmacol. 2016 Aug 11;8:93-107. doi: 10.2147/CPAA.S105165.

19.

Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP.

Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Review.

20.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Review.

PMID:
22740145

Supplemental Content

Support Center